This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Cognitive dysfunction

GABAA receptor a5 (GABRA5)

Mouse studies suggest selective GABRA5 negative allosteric modulators could help treat cognitive dysfunction in Down syndrome. In a transgenic mouse model for Down syndrome, the GABRA5 negative allosteric modulator RO4938581 increased spatial learning, memory and attention compared with vehicle. In these mice, RO4938581 did not induce anxiety-like behaviors or convulsions. Next steps include additional preclinical studies with RO4938581.
Roche has RG1662 in Phase I testing to treat Alzheimer's disease (AD) and cognitive dysfunction associated with Down syndrome.

SciBX 6(9); doi:10.1038/scibx.2013.221
Published online March 7, 2013

Patented; unavailable for licensing

Martínez-Cué, C. et al. J. Neurosci.; published online Feb. 27, 2013;
doi:10.1523/JNEUROSCI.1203-12.2013
Contact: Maria-Clemencia Hernández, Roche, Basel, Switzerland
e-mail:

maria-clemencia.hernandez@roche.com